Recruitment of clinical research volunteers (lung cancer)
The Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with advanced non-small cell lung cancer (NSCLC) with a human epidermal growth factor receptor 2 (HER2) gene mutation, please contact us. We will conduct an initial assessment to determine your eligibility for this clinical trial. Drug and imaging scans are free of charge. However, patients must understand the purpose of the study and any potential risks.
Research name
A study to further compare the efficacy and safety of BAY 2927088 and standard therapy in participants with advanced non-small cell lung cancer (NSCLC) with mutations in the human epidermal growth factor receptor 2 (HER2) gene
A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations.
ClinicalTrials.gov Identifier: NCT06452277 (View detailed trial information)
Patient eligibility
- Patients with advanced non-small cell lung cancer (NSCLC) with mutations in the human epidermal growth factor receptor 2 (HER2) gene
Research remuneration
- Related treatment drugs, image scans and doctor's consultations are free of charge
Research process
If you are eligible to participate in this study, you will be treated with BAY 2927088 or Pembrolizumab plus chemotherapy (i.e. Pemetrexed and Carboplatin/Cisplatin) until the end of treatment or your condition worsens.
Related risks
During the study period, you may experience discomfort and risk due to treatment with BAY 2927088 or Pembrolizumab plus chemotherapy (i.e. Pemetrexed and Carboplatin/Cisplatin). Discomfort and risk may vary from person to person.
Contact method
Interested participants can contact us through the following methods for further understanding：
- WhatsApp：5518 2992
- Telephone：+852 2386 8002
- Email：Enquiry@hkuoc.hk
- WeChat: hkuoc23868002
Related resources
Inquire about more research projects：Clinical Research Page of the United Cancer Centre of Hong Kong
Learn more about non-small cell lung cancer:Hong Kong Hospital Authority-Lung Cancer Information
Research sponsor
Bayer